Key Findings
The Department of Veterans Affairs announced in August 2026 the launch of the PIVOT trial (Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression), a landmark multisite, randomized, controlled study conducted in partnership with Compass Pathways. The trial aims to enroll at least 240 veterans diagnosed with treatment-resistant depression and comorbid PTSD across multiple VA medical centers, with data collection running through 2031.
Participants will receive a single 25mg dose of synthetic psilocybin (COMP360) alongside structured psychological support sessions — including preparatory sessions, guided dosing, and integration therapy. The primary endpoint is change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores at 3 weeks post-dosing, with secondary measures tracking PTSD symptom severity (PCL-5), suicidal ideation, functional capacity, and quality of life over 12 months.
This trial follows a separate Nature Medicine publication from August 2026 demonstrating that a single 25mg psilocybin dose, paired with psychological support, produced sustained reductions in depressive symptoms in a public healthcare setting — the first large-scale evidence of psilocybin efficacy outside private clinical trial infrastructure.
Why This Matters for Body-Mind Practice
The PIVOT trial represents the largest federally funded psilocybin study in US history and a fundamental shift in how the VA approaches treatment-resistant mental health conditions in veterans. For body-mind practitioners, the trial's integration therapy protocol — which includes somatic awareness, breathwork, and mindfulness-based practices during both preparation and integration phases — validates the role of embodied practices in psychedelic-assisted therapy. The study's longitudinal design will generate the most rigorous data yet on whether psilocybin-induced neuroplasticity translates to durable nervous system recalibration in trauma-affected populations.
Source
- VA PIVOT Trial: Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression. — Department of Veterans Affairs
